A. Yu. Grishina
A. Yu. Grishina has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy Yur'Evich Ivkin
Center of Experimental Pharmacology, St. Petersburg State Chemical Pharmaceutical University, 14 Prof. Popov Str., 197022 Saint-Petersburg, Russia
7 shared publications - A. S. Ivanov
Saint Petersburg State Chemical and Pharmaceutical University (SPCPU)
2 shared publications - E. I. Yeletskaya
Saint-Petersburg State Chemical and Pharmaceutical University
2 shared publications - Irina A. Titovich
Saint Petersburg State Chemical and Pharmaceutical University (SPCPU)
2 shared publications - Olga Vladimirovna Buyuklinskaya
Saint-Petersburg State Chemical and Pharmaceutical University
2 shared publications - Sergey Vladimirovich Okovityi
Saint Petersburg State Chemical and Pharmaceutical University; Saint Petersburg State University
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (3) , 227-240
Comparative nephroprotective efficacy of malonic acid derivatives (etmaben and maloben) in renal ischemia-reperfusion injury in rats
Introduction. This study assessed the nephroprotective potential of malonic acid derivatives (MADs) in acute and subacute ischemic renal injury. A model of prerenal failure was simulated using 60-minute warm renal ischemia. Aim. To study the nephroprotective effect of MADs in acute and subacute ischemic renal failure. Materials and methods. The experiment was conducted using a model of warm renal ischemia induced by 60-minute occlusion of the right renal artery. During a month-long monotherapy course, the effects of 4-[(3-ethoxy-3-oxopropanoyl) amino]benzoic acid (etmaben, 60 mg/kg) and sodium 4,4'-(propanediamido)dibenzoate (maloben, 60 mg/kg) were compared with the reference drug, ethylmethylhydroxypyridine succinate (Mexidol®, 50 mg/kg). To assess renal function on days 3 and 30 after ischemia, serum creatinine and urea concentrations, glomerular filtration rate (GFR), creatinine clearance, electrolyte excretion rate, and antioxidant gene expression were analyzed, and histological examination was performed. Results and discussion. The obtained data indicate the significant efficacy of MADs in the treatment of acute ischemic kidney injury. In the group of animals receiving etmaben, a statistically significant decrease in serum creatinine and urea levels, as well as an increase in glomerular filtration rate, was observed, with no significant effect on diuresis. Maloben, in turn, had a more pronounced effect on diuresis and electrolyte excretion during the acute period. Both studied compounds demonstrated the ability to improve renal excretory function, manifested by increased creatinine elimination and a reduction in the severity of the oligoanuric phase of acute nephropathy. Conclusion. It was found that the studied drugs activate renal excretory function, contribute to the normalization of creatinine clearance and the attenuation of the manifestations of acute oligoanuric syndrome, stabilizing the condition of animals with acute kidney injury.
- 9 September 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (3) , 227-240
Open AccessComparative nephroprotective efficacy of malonic acid derivatives (etmaben and maloben) in renal ischemia-reperfusion injury in rats
Introduction. This study assessed the nephroprotective potential of malonic acid derivatives (MADs) in acute and subacute ischemic renal injury. A model of prerenal failure was simulated using 60-minute warm renal ischemia. Aim. To study the nephroprotective effect of MADs in acute and subacute ischemic renal failure. Materials and methods. The experiment was conducted using a model of warm renal ischemia induced by 60-minute occlusion of the right renal artery. During a month-long monotherapy course, the effects of 4-[(3-ethoxy-3-oxopropanoyl) amino]benzoic acid (etmaben, 60 mg/kg) and sodium 4,4'-(propanediamido)dibenzoate (maloben, 60 mg/kg) were compared with the reference drug, ethylmethylhydroxypyridine succinate (Mexidol®, 50 mg/kg). To assess renal function on days 3 and 30 after ischemia, serum creatinine and urea concentrations, glomerular filtration rate (GFR), creatinine clearance, electrolyte excretion rate, and antioxidant gene expression were analyzed, and histological examination was performed. Results and discussion. The obtained data indicate the significant efficacy of MADs in the treatment of acute ischemic kidney injury. In the group of animals receiving etmaben, a statistically significant decrease in serum creatinine and urea levels, as well as an increase in glomerular filtration rate, was observed, with no significant effect on diuresis. Maloben, in turn, had a more pronounced effect on diuresis and electrolyte excretion during the acute period. Both studied compounds demonstrated the ability to improve renal excretory function, manifested by increased creatinine elimination and a reduction in the severity of the oligoanuric phase of acute nephropathy. Conclusion. It was found that the studied drugs activate renal excretory function, contribute to the normalization of creatinine clearance and the attenuation of the manifestations of acute oligoanuric syndrome, stabilizing the condition of animals with acute kidney injury.
- 22 May 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Development, validation and testing of the HPLC-UV bioanalytical method for quantification of etmaben in blood plasma and organs of rats
Introduction. Currently, the search and development of innovative cardiotropic drugs is an urgent task for pharmaceutical science. One such drug is a derivative of malonic acid, etmaben, which was synthesized at the St. Petersburg State Chemical and Pharmaceutical University (SPCPU). To conduct preclinical and clinical studies, it is necessary to develop and validate a bioanalytical method that allows for the quantitative determination of etmaben in complex biological matrices with minimal time and resource requirements. Aim. The aim of the study is to develop and validate a method for the determination of etmaben in the blood plasma and organs of laboratory animals using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) followed by testing and obtaining a pool of data on the distribution of etmaben in the organs and tissues of experimental animals. Materials and methods. The development and validation of the bioanalytical method, as well as the quantitative determination of etmaben, were performed on a Flexar liquid chromatograph (PerkinElmer, USA) equipped with a UV detector and a thermostatted autosampler, using a Kromasil 100, 150 × 2.1, C8, 3.5 μm column (AkzoNobel, Netherlands). Detection was performed at a wavelength of 270 nm. A pharmacological experiment to test the method was conducted on 20 outbred male rats (Kurchatov Institute – "Rappolovo", Russia), divided into a control group (intact animals, n = 10) and a group with experimental chronic heart failure (CHF) ( n = 10), a model of which was induced by ligation of the left coronary artery. All animals received etmaben intragastrically at a dose of 60 mg/kg for 30 days. Whole blood samples were collected for analysis on day 30, and organs (heart and kidneys) were isolated. Etmaben was quantified in plasma and tissue homogenates using HPLC-UV after sample preparation, including protein precipitation with acetonitrile (HPLC Grade, cat. no. A/0627/17, Thermo Fisher Scientific, USA). Results and discussion. Optimal conditions for the chromatographic determination of etmaben in biological matrices (blood plasma and tissue homogenates) using HPLC-UV were developed. The developed method was validated using the following validation parameters: selectivity, calibration curve, accuracy, precision, lower limit of quantification (LLOQ), carryover effect, no effect of sample dilution and stability. The degree of etmaben recovery from the matrix was also assessed. The LLOQ for etmaben was 5.0 ng/mL. The developed method was successfully applied to assess etmaben distribution in the organs and tissues of laboratory animals at specific stages of preclinical testing. In CHF, plasma concentrations of etmaben doubled, and in pathologically altered myocardium, they increased by 47 % compared to control animals. Conclusion. A bioanalytical method for determining etmaben using HPLC-UV was developed and validated. It was tested during preclinical trials to study the drug's distribution in organs and tissues of experimental animals. The observed selective accumulation of etmaben in damaged myocardium confirms its therapeutic relevance for the treatment of CHF.
- 22 May 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Development, validation and testing of the HPLC-UV bioanalytical method for quantification of etmaben in blood plasma and organs of rats
Introduction. Currently, the search and development of innovative cardiotropic drugs is an urgent task for pharmaceutical science. One such drug is a derivative of malonic acid, etmaben, which was synthesized at the St. Petersburg State Chemical and Pharmaceutical University (SPCPU). To conduct preclinical and clinical studies, it is necessary to develop and validate a bioanalytical method that allows for the quantitative determination of etmaben in complex biological matrices with minimal time and resource requirements. Aim. The aim of the study is to develop and validate a method for the determination of etmaben in the blood plasma and organs of laboratory animals using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) followed by testing and obtaining a pool of data on the distribution of etmaben in the organs and tissues of experimental animals. Materials and methods. The development and validation of the bioanalytical method, as well as the quantitative determination of etmaben, were performed on a Flexar liquid chromatograph (PerkinElmer, USA) equipped with a UV detector and a thermostatted autosampler, using a Kromasil 100, 150 × 2.1, C8, 3.5 μm column (AkzoNobel, Netherlands). Detection was performed at a wavelength of 270 nm. A pharmacological experiment to test the method was conducted on 20 outbred male rats (Kurchatov Institute – "Rappolovo", Russia), divided into a control group (intact animals, n = 10) and a group with experimental chronic heart failure (CHF) ( n = 10), a model of which was induced by ligation of the left coronary artery. All animals received etmaben intragastrically at a dose of 60 mg/kg for 30 days. Whole blood samples were collected for analysis on day 30, and organs (heart and kidneys) were isolated. Etmaben was quantified in plasma and tissue homogenates using HPLC-UV after sample preparation, including protein precipitation with acetonitrile (HPLC Grade, cat. no. A/0627/17, Thermo Fisher Scientific, USA). Results and discussion. Optimal conditions for the chromatographic determination of etmaben in biological matrices (blood plasma and tissue homogenates) using HPLC-UV were developed. The developed method was validated using the following validation parameters: selectivity, calibration curve, accuracy, precision, lower limit of quantification (LLOQ), carryover effect, no effect of sample dilution and stability. The degree of etmaben recovery from the matrix was also assessed. The LLOQ for etmaben was 5.0 ng/mL. The developed method was successfully applied to assess etmaben distribution in the organs and tissues of laboratory animals at specific stages of preclinical testing. In CHF, plasma concentrations of etmaben doubled, and in pathologically altered myocardium, they increased by 47 % compared to control animals. Conclusion. A bioanalytical method for determining etmaben using HPLC-UV was developed and validated. It was tested during preclinical trials to study the drug's distribution in organs and tissues of experimental animals. The observed selective accumulation of etmaben in damaged myocardium confirms its therapeutic relevance for the treatment of CHF.
- Open Access
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 30-42
Development of medicines based on 5-phenyltetrazole derivatives for the pharmacological correction of metabolic phenomena
Introduction. Many compounds containing a tetrazole component are superior in efficacy to other antidiabetic drugs in preclinical studies, and some candidates are already in current trials. The widespread use of tetrazole derivatives to target diabetes-associated targets and therapies that maintain their stability provide the basis for the development of new, effective antidiabetic agents. Aim. A study ( in silico , synthesis, in vivo ) of a series of hybrid 5-phenyltetrazole derivatives was conducted to identify and conduct experimental validation of promising compounds exhibiting hypoglycemic and anti-fat activity. Materials and methods. The synthesis of hybrid heterocyclic compounds was accomplished by acylation of a series of heterocyclic derivatives of N -alkyl-5-aminotetrazole, 4-amino-4 H -1,2,4-triazole-3-thiol, and 2-hydrazinyl-4,6-dimethylpyrimidine with 5-phenyltetrazol-2-ylacetic acid chloride. Results and discussion. As a result of in silico (PASS, docking, scoring) study of biological activity in a series of 5-phenyltetrazole derivatives, the most promising "hybrid" (polynuclear) heterocyclic compounds were identified: N '-(4,6-dimethylpyrimidin-2-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetohydrazide, N -(3-mercapto-4 H -1,2,4-triazol-4-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide, N -(1-methyl-1 H -tetrazol-5-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide, N -(2-methyl-2 H -tetrazol-5-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide and N- tert-butyl-2-({1-[2-(5-phenyl-2 H -tetrazol-2-yl)acetamido]-1 H -tetrazol-5-yl}thio)acetamide. These predictions are of interest as potential computer-aided means for the pharmacological correction of various metabolic phenomena. A rational method for synthesizing these compounds was developed and implemented, the structure and individuality of which were demonstrated using modern instrumental physicochemical methods. In vivo studies demonstrated that these heterocyclic compounds exhibit hypoglycemic and pronounced anti-lipid activity. Conclusion. The study of hybrid 5-phenyltetrazole derivatives revealed pronounced hypoglycemic activity. It was found that the anti-lipid activity in this case is not directly related to the hypoglycemic effect, unlike the manifestation characteristic of the sensitizer metformin.
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 30-42
Open AccessDevelopment of medicines based on 5-phenyltetrazole derivatives for the pharmacological correction of metabolic phenomena
Introduction. Many compounds containing a tetrazole component are superior in efficacy to other antidiabetic drugs in preclinical studies, and some candidates are already in current trials. The widespread use of tetrazole derivatives to target diabetes-associated targets and therapies that maintain their stability provide the basis for the development of new, effective antidiabetic agents. Aim. A study ( in silico , synthesis, in vivo ) of a series of hybrid 5-phenyltetrazole derivatives was conducted to identify and conduct experimental validation of promising compounds exhibiting hypoglycemic and anti-fat activity. Materials and methods. The synthesis of hybrid heterocyclic compounds was accomplished by acylation of a series of heterocyclic derivatives of N -alkyl-5-aminotetrazole, 4-amino-4 H -1,2,4-triazole-3-thiol, and 2-hydrazinyl-4,6-dimethylpyrimidine with 5-phenyltetrazol-2-ylacetic acid chloride. Results and discussion. As a result of in silico (PASS, docking, scoring) study of biological activity in a series of 5-phenyltetrazole derivatives, the most promising "hybrid" (polynuclear) heterocyclic compounds were identified: N '-(4,6-dimethylpyrimidin-2-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetohydrazide, N -(3-mercapto-4 H -1,2,4-triazol-4-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide, N -(1-methyl-1 H -tetrazol-5-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide, N -(2-methyl-2 H -tetrazol-5-yl)-2-(5-phenyl-2 H -tetrazol-2-yl)-acetamide and N- tert-butyl-2-({1-[2-(5-phenyl-2 H -tetrazol-2-yl)acetamido]-1 H -tetrazol-5-yl}thio)acetamide. These predictions are of interest as potential computer-aided means for the pharmacological correction of various metabolic phenomena. A rational method for synthesizing these compounds was developed and implemented, the structure and individuality of which were demonstrated using modern instrumental physicochemical methods. In vivo studies demonstrated that these heterocyclic compounds exhibit hypoglycemic and pronounced anti-lipid activity. Conclusion. The study of hybrid 5-phenyltetrazole derivatives revealed pronounced hypoglycemic activity. It was found that the anti-lipid activity in this case is not directly related to the hypoglycemic effect, unlike the manifestation characteristic of the sensitizer metformin.
- Open Access
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 270-279
The role of malonic acid derivate in the modulation of metabolic pathways in the kidneys during chronic heart failure
Introduction. Chronic heart failure (CHF) often leads to progressive renal dysfunction; however, pharmacological protection strategies aimed at correcting metabolic and oxidative disturbances in renal tissue remain underdeveloped. In this regard, it seems relevant to study the effect of new compounds, such as malonic acid derivatives, including 4-[(3-ethoxy-3-oxopropanoyl) amino]benzoic acid (etmaben), on the expression of genes encoding key enzymes of metabolic and antioxidant pathways in the kidneys in CHF. Previously, a more pronounced nephroprotective effect was detected for etmaben than for another malonate, maloben. Aim. To evaluate the effect of 4-[(3-ethoxy-3-oxopropanoyl)amino]benzoic acid on the expression of genes regulating enzymatic pathways in the kidneys of rats with experimental CHF. Materials and methods. The study was conducted on 30 outbred white male rats (300–350 g) housed under standard conditions (12-hour light/dark cycle, temperature 22 ± 2 °C, humidity 50–60 %, with ad libitum access to food and water). The animals were divided into three groups. Group 1 (Control–) consisted of healthy animals ( n = 10) that received purified water (1 mL/kg/day, intragastrically). Group 2 (CHF–) included animals with chronic heart failure (CHF, n = 10) that were administered purified water (1 mL/kg/day, intragastrically) starting from day 30 after the surgery. Group 3 (CHF+) was composed of animals with CHF ( n = 10) that received etmaben (60 mg/kg/day, intragastrically) starting from day 30 after the surgery. CHF was modeled by ligation of the left coronary artery. Successful model induction was confirmed echocardiographically (ejection fraction –ddCt method with normalization to the reference gene B2M. Results and discussion. It was found that CHF led to significant activation of the transcription factor Nrf2; however, the expression level of its target gene, GPx1, remained unchanged both in CHF and after etmaben treatment, indicating impaired functioning of this signaling pathway. Administration of 4-[(3-ethoxy-3-oxopropanoyl)amino]benzoic acid caused a statistically significant increase in the expression of the Cpt1b gene ( p < 0.05), suggesting a shift in cellular metabolism towards fatty acid β-oxidation. Furthermore, significant suppression of the pro-oxidant enzyme Nox1 and activation of the thioredoxin reductase 1 (Txnrd1) gene ( p < 0.05) were recorded in the treatment groups. The Notch signaling pathway was activated by etmaben, as evidenced by increased expression of the Hes1 gene ( p < 0.05), while no significant effect on the expression of the mTOR gene was detected. Conclusion. Etmaben functions as a metabolic modulator and redox regulator. Its action is not associated with direct antioxidant activity but is due to the activation of adaptive mechanisms: reducing the demand for antioxidant defense by suppressing sources of reactive oxygen species (Nox1), activating a key regulator of the antioxidant response (Nrf2), and altering energy metabolism through the induction of Cpt1b and Glud1.
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 270-279
Open AccessThe role of malonic acid derivate in the modulation of metabolic pathways in the kidneys during chronic heart failure
Introduction. Chronic heart failure (CHF) often leads to progressive renal dysfunction; however, pharmacological protection strategies aimed at correcting metabolic and oxidative disturbances in renal tissue remain underdeveloped. In this regard, it seems relevant to study the effect of new compounds, such as malonic acid derivatives, including 4-[(3-ethoxy-3-oxopropanoyl) amino]benzoic acid (etmaben), on the expression of genes encoding key enzymes of metabolic and antioxidant pathways in the kidneys in CHF. Previously, a more pronounced nephroprotective effect was detected for etmaben than for another malonate, maloben. Aim. To evaluate the effect of 4-[(3-ethoxy-3-oxopropanoyl)amino]benzoic acid on the expression of genes regulating enzymatic pathways in the kidneys of rats with experimental CHF. Materials and methods. The study was conducted on 30 outbred white male rats (300–350 g) housed under standard conditions (12-hour light/dark cycle, temperature 22 ± 2 °C, humidity 50–60 %, with ad libitum access to food and water). The animals were divided into three groups. Group 1 (Control–) consisted of healthy animals ( n = 10) that received purified water (1 mL/kg/day, intragastrically). Group 2 (CHF–) included animals with chronic heart failure (CHF, n = 10) that were administered purified water (1 mL/kg/day, intragastrically) starting from day 30 after the surgery. Group 3 (CHF+) was composed of animals with CHF ( n = 10) that received etmaben (60 mg/kg/day, intragastrically) starting from day 30 after the surgery. CHF was modeled by ligation of the left coronary artery. Successful model induction was confirmed echocardiographically (ejection fraction –ddCt method with normalization to the reference gene B2M. Results and discussion. It was found that CHF led to significant activation of the transcription factor Nrf2; however, the expression level of its target gene, GPx1, remained unchanged both in CHF and after etmaben treatment, indicating impaired functioning of this signaling pathway. Administration of 4-[(3-ethoxy-3-oxopropanoyl)amino]benzoic acid caused a statistically significant increase in the expression of the Cpt1b gene ( p < 0.05), suggesting a shift in cellular metabolism towards fatty acid β-oxidation. Furthermore, significant suppression of the pro-oxidant enzyme Nox1 and activation of the thioredoxin reductase 1 (Txnrd1) gene ( p < 0.05) were recorded in the treatment groups. The Notch signaling pathway was activated by etmaben, as evidenced by increased expression of the Hes1 gene ( p < 0.05), while no significant effect on the expression of the mTOR gene was detected. Conclusion. Etmaben functions as a metabolic modulator and redox regulator. Its action is not associated with direct antioxidant activity but is due to the activation of adaptive mechanisms: reducing the demand for antioxidant defense by suppressing sources of reactive oxygen species (Nox1), activating a key regulator of the antioxidant response (Nrf2), and altering energy metabolism through the induction of Cpt1b and Glud1.
- Open Access
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 208-220
Subacute toxicity, local irritant, and allergenic effects of Hedysarum semenowii extract
Introduction. Hedysarum semenowii Regel & Herder of the genus Hedysarum L., possess a rich phyto-chemical profile and hold promise as a foundation for developing novel pharmaceuticals. Despite the recognized pharmacological activities of various Hedysarum L. species, their safety profiles have not been sufficiently studied, necessitating further investigation to evaluate their toxicity and potential adverse effects. To address this gap, a study was conducted to assess the subacute toxicity, local irritant effects, and allergenicity of Hedysarum semenowii extract, with the aim of determining its safety and therapeutic potential. Aim. Determination of subacute toxicity, local irritant effect and allergenicity of the Hedysarum semenowii Regel & Herder extract. Materials and methods. The subacute toxicity study was performed using outbred rats, with the extract from aerial part of the plant administered orally at doses of 500, 2000, and 5000 mg/kg over a 28-day period. The condition of the animals was monitored throughout the study. At the conclusion of the subacute toxicity evaluation, pathological changes in the liver and kidneys of the experimental animals were examined. Local irritant and allergenic effects were assessed in rats and guinea pigs, respectively, employing visual inspection and the Draize scoring system. Results and discussion. The 28-day subacute toxicity study revealed no significant toxicity, mortality, or behavioral changes in the animals. Body weight, food consumption, and water intake remained stable across all groups. According to the results of macroscopic and microscopic examination, minor physiological changes were noted in the liver and kidneys, the severity of which correlated with the administered doses of the extract. Furthermore, the extract did not induce skin irritation or allergenic reactions in tests involving rats and guinea pigs. Conclusion. Hedysarum semenowii extract exhibited low toxicity and an absence of irritant and allergenic effects, affirming its safety and potential for further exploration as a therapeutic agent.
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 208-220
Open AccessSubacute toxicity, local irritant, and allergenic effects of Hedysarum semenowii extract
Introduction. Hedysarum semenowii Regel & Herder of the genus Hedysarum L., possess a rich phyto-chemical profile and hold promise as a foundation for developing novel pharmaceuticals. Despite the recognized pharmacological activities of various Hedysarum L. species, their safety profiles have not been sufficiently studied, necessitating further investigation to evaluate their toxicity and potential adverse effects. To address this gap, a study was conducted to assess the subacute toxicity, local irritant effects, and allergenicity of Hedysarum semenowii extract, with the aim of determining its safety and therapeutic potential. Aim. Determination of subacute toxicity, local irritant effect and allergenicity of the Hedysarum semenowii Regel & Herder extract. Materials and methods. The subacute toxicity study was performed using outbred rats, with the extract from aerial part of the plant administered orally at doses of 500, 2000, and 5000 mg/kg over a 28-day period. The condition of the animals was monitored throughout the study. At the conclusion of the subacute toxicity evaluation, pathological changes in the liver and kidneys of the experimental animals were examined. Local irritant and allergenic effects were assessed in rats and guinea pigs, respectively, employing visual inspection and the Draize scoring system. Results and discussion. The 28-day subacute toxicity study revealed no significant toxicity, mortality, or behavioral changes in the animals. Body weight, food consumption, and water intake remained stable across all groups. According to the results of macroscopic and microscopic examination, minor physiological changes were noted in the liver and kidneys, the severity of which correlated with the administered doses of the extract. Furthermore, the extract did not induce skin irritation or allergenic reactions in tests involving rats and guinea pigs. Conclusion. Hedysarum semenowii extract exhibited low toxicity and an absence of irritant and allergenic effects, affirming its safety and potential for further exploration as a therapeutic agent.
- Open Access
- 26 December 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Use of an electrical stimulation-induced fatigue protocol to evaluate the myotropic effects of metabolic-active agents in db/db mice
Introduction. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance, impaired glucose tolerance, and hyperglycaemia. T2DM is a proven risk factor for peripheral neuropathies as well as muscle contractility and function impairments. The biguanide metformine, experimental compound maloben, and preparations of various Panax species have a considerable potential for the treatment of T2DM and its skeletal muscle complications. As a test to evaluate muscle contractility and the effectiveness of its recovery, Gregory et al. have developed a protocol of electrical stimulation-induced fatigue (ESIF) which includes measuring grip strength after fatiguing the biceps brachii muscle with high-frequency electrical stimulation using implantable electrodes.Aim. In this work, we attempted to assess the applicability of a modification of said protocol in order to evaluate the myotropic effects of metformin, maloben, and extracts from suspension cell cultures of Panax ginseng C.A. Mey. (PGE), P. vietnamensis Ha & Grushv. (PVE), and P. japonicus (T. Nees) C.A. Mey. (PJE) in the leptin-resistant db/db mice, one of the most popular modern T2DM models.Materials and methods. The experiments were carried out in 60 young adult (2 months old) male C57Bl/Ks-db+/+m (db/db) mice weighing 45–50 g, randomized into 6 groups: 1) Control (n = 10; 0.9 % saline); 2) PGE (n = 10; 50 mg/kg); 3) PVE (n = 10; 50 mg/kg); 4) PJE (n = 10; 50 mg/kg); 5) maloben (n = 10; 60 mg/kg); 6) metformin (n = 10; 300 mg/kg). All drugs were administered via oral gavage using a feeding tube once daily for 2 months. Following the treatment period, forelimb and all-four limb grip strength (g) was assessed using the Grip Strength Meter (TSE Systems, Germany). Using stimulation electroneuromyography, we measured the compound muscle action potential (CMAP) amplitudes in the gastrocnemius induced by single-stimulus sciatic nerve stimulation, and assessed the dynamics of CMAP amplitudes during the first 5 min following the ESIF protocol completion.Results and discussion. Following treatment period completion, no significant changes were observed between the groups in grip strength or gastrocnemius CMAP amplitude under single-stimulus stimulation. Controlled ESIF of the muscle caused a 18.83–35.23 % (relative to baseline) decrease in CMAP amplitudes (p < 0.01 for all groups) that was significantly smaller in the PVE, PJE, and maloben groups vs. control (p < 0.05). The post-ESIF recovery period was associated with a 10.18–14.79 % increase in CMAP amplitudes that was significant in all groups except PGE (p < 0.01 for control, PVE, and PJE; p < 0.05 for maloben and metformin). No significant differences from control were observed in any of the treatment groups regarding net recovery.Сonclusion. The proposed protocol represents a functional test suitable to assess the recovery effectiveness of electrical activity of a skeletal muscle following its controlled fatigue. Using the described protocol, we were able to detect beneficial effects of PVE, PJE, and maloben (but not PGE or metformin) on the recovery of gastrocnemius contractility following tetanization in diabetic db/db mice. The ESIF test is sensitive to the myotropic effects of metabolic agents, minimally invasive, and acceptable under chronic experiment conditions.
- 26 December 2024
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessUse of an electrical stimulation-induced fatigue protocol to evaluate the myotropic effects of metabolic-active agents in db/db mice
Introduction. Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance, impaired glucose tolerance, and hyperglycaemia. T2DM is a proven risk factor for peripheral neuropathies as well as muscle contractility and function impairments. The biguanide metformine, experimental compound maloben, and preparations of various Panax species have a considerable potential for the treatment of T2DM and its skeletal muscle complications. As a test to evaluate muscle contractility and the effectiveness of its recovery, Gregory et al. have developed a protocol of electrical stimulation-induced fatigue (ESIF) which includes measuring grip strength after fatiguing the biceps brachii muscle with high-frequency electrical stimulation using implantable electrodes.Aim. In this work, we attempted to assess the applicability of a modification of said protocol in order to evaluate the myotropic effects of metformin, maloben, and extracts from suspension cell cultures of Panax ginseng C.A. Mey. (PGE), P. vietnamensis Ha & Grushv. (PVE), and P. japonicus (T. Nees) C.A. Mey. (PJE) in the leptin-resistant db/db mice, one of the most popular modern T2DM models.Materials and methods. The experiments were carried out in 60 young adult (2 months old) male C57Bl/Ks-db+/+m (db/db) mice weighing 45–50 g, randomized into 6 groups: 1) Control (n = 10; 0.9 % saline); 2) PGE (n = 10; 50 mg/kg); 3) PVE (n = 10; 50 mg/kg); 4) PJE (n = 10; 50 mg/kg); 5) maloben (n = 10; 60 mg/kg); 6) metformin (n = 10; 300 mg/kg). All drugs were administered via oral gavage using a feeding tube once daily for 2 months. Following the treatment period, forelimb and all-four limb grip strength (g) was assessed using the Grip Strength Meter (TSE Systems, Germany). Using stimulation electroneuromyography, we measured the compound muscle action potential (CMAP) amplitudes in the gastrocnemius induced by single-stimulus sciatic nerve stimulation, and assessed the dynamics of CMAP amplitudes during the first 5 min following the ESIF protocol completion.Results and discussion. Following treatment period completion, no significant changes were observed between the groups in grip strength or gastrocnemius CMAP amplitude under single-stimulus stimulation. Controlled ESIF of the muscle caused a 18.83–35.23 % (relative to baseline) decrease in CMAP amplitudes (p < 0.01 for all groups) that was significantly smaller in the PVE, PJE, and maloben groups vs. control (p < 0.05). The post-ESIF recovery period was associated with a 10.18–14.79 % increase in CMAP amplitudes that was significant in all groups except PGE (p < 0.01 for control, PVE, and PJE; p < 0.05 for maloben and metformin). No significant differences from control were observed in any of the treatment groups regarding net recovery.Сonclusion. The proposed protocol represents a functional test suitable to assess the recovery effectiveness of electrical activity of a skeletal muscle following its controlled fatigue. Using the described protocol, we were able to detect beneficial effects of PVE, PJE, and maloben (but not PGE or metformin) on the recovery of gastrocnemius contractility following tetanization in diabetic db/db mice. The ESIF test is sensitive to the myotropic effects of metabolic agents, minimally invasive, and acceptable under chronic experiment conditions.
- Open Access
- 24 November 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Choleotropic Activity of Cistus salviifolius Extract
Introduction. It is known that a number of species of the genus Cistus are used in Mediterranean folk medicine in the form of infusions and herbal teas to treat digestive problems and acute respiratory virus infection. Empirical data have accumulated that sage incense extract improves the condition of patients with chronic cholestatic liver diseases (CLDs). Currently, only ursodeoxycholic acid (UDCA) is the generally accepted drug for the treatment of most CLDs.Aim. Comparative efficacy evaluation of Cistus salviifolius extract (at 2 doses levels) compared to the reference medicine ursodeoxycholic acid Ursosan® (at a therapeutic dose) in intragastric administration to mice in a cholestasis model induced by intragastric administration of alphanaphthylisothiocyanate (ANIT) oil solution during 20 Days.Materials and methods. The cholestase model was induced by intragastric administration of an alpha-naphthylisothiocyanate oil solution to mice during 20 days. The following biochemical parameters were determined in the serum of experimental animals: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, total cholesterol, bilirubin, triglycerides, albumins. Histological analysis was performed on the liver and gallbladder.Results and discussion. Cistus salviifolius extract at a therapeutic dose of 253 mg/kg and at a dose exceeding the therapeutic dose (506 mg/kg), as well as the reference medicine of Ursodeoxycholic acid Ursosan® at a therapeutic dose of 150 mg/kg reduced the level of aspartate aminotransferase in serum increased after ANIT administration to a level of the control group without pathology. Deviations of other parameters from the control group (alanine aminotransferase, alkaline phosphatase, total protein, total cholesterol, bilirubin, triglycerides, albumins) were statistically insignificant. Histological analysis of the liver and gallbladder demonstrated that the severity of ballooning degeneration and cholecystitis were significantly reduced in groups which was treated by Cistus salviifolius extract at two doses, but not in the group with reference drug. The severity of cholestasis was poorly influenced by Cistus salviifolius extract in contrast to ursodeoxycholic acid, which was more effective for this pathology.Conclusion. The conducted study against the background of reports on the effectiveness of the Cistus salviifolius extract in clinical practice allows to recommend its use as a component of combined therapy of a patient with hepatobiliary pathology and as a pharmacoprevention in healthy people in the presence of risk factors.
- 24 November 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessCholeotropic Activity of Cistus salviifolius Extract
Introduction. It is known that a number of species of the genus Cistus are used in Mediterranean folk medicine in the form of infusions and herbal teas to treat digestive problems and acute respiratory virus infection. Empirical data have accumulated that sage incense extract improves the condition of patients with chronic cholestatic liver diseases (CLDs). Currently, only ursodeoxycholic acid (UDCA) is the generally accepted drug for the treatment of most CLDs.Aim. Comparative efficacy evaluation of Cistus salviifolius extract (at 2 doses levels) compared to the reference medicine ursodeoxycholic acid Ursosan® (at a therapeutic dose) in intragastric administration to mice in a cholestasis model induced by intragastric administration of alphanaphthylisothiocyanate (ANIT) oil solution during 20 Days.Materials and methods. The cholestase model was induced by intragastric administration of an alpha-naphthylisothiocyanate oil solution to mice during 20 days. The following biochemical parameters were determined in the serum of experimental animals: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, total cholesterol, bilirubin, triglycerides, albumins. Histological analysis was performed on the liver and gallbladder.Results and discussion. Cistus salviifolius extract at a therapeutic dose of 253 mg/kg and at a dose exceeding the therapeutic dose (506 mg/kg), as well as the reference medicine of Ursodeoxycholic acid Ursosan® at a therapeutic dose of 150 mg/kg reduced the level of aspartate aminotransferase in serum increased after ANIT administration to a level of the control group without pathology. Deviations of other parameters from the control group (alanine aminotransferase, alkaline phosphatase, total protein, total cholesterol, bilirubin, triglycerides, albumins) were statistically insignificant. Histological analysis of the liver and gallbladder demonstrated that the severity of ballooning degeneration and cholecystitis were significantly reduced in groups which was treated by Cistus salviifolius extract at two doses, but not in the group with reference drug. The severity of cholestasis was poorly influenced by Cistus salviifolius extract in contrast to ursodeoxycholic acid, which was more effective for this pathology.Conclusion. The conducted study against the background of reports on the effectiveness of the Cistus salviifolius extract in clinical practice allows to recommend its use as a component of combined therapy of a patient with hepatobiliary pathology and as a pharmacoprevention in healthy people in the presence of risk factors.
- 7 April 2023
- Published by Open Systems Publications in Лечащий врач
- No. 4(26)
Benefits of ebastine from the position of clinical pharmacology
The article reviews data on pharmacokinetics, pharmacodynamics, efficacy and safety of ebastine, presents reviews of the most significant clinical trials in the treatment of allergic diseases (allergic rhinitis, urticaria) and comparative studies with other antihistamine drugs available in the arsenal of a modern practical doctor. Data of multiple preclinical and clinical trials presented in domestic and foreign sources allow to demonstrate its effectiveness and safety widely. Ebastin is characterized as medicine with high enough safety profile due to absence of sedative, atropine-like and cardiotropic effects, absence of tachyphylaxis and interaction with other medicines, absence of influence on ability to drive motor transport and complicated mechanisms. Pharmacokinetic properties of ebastine characterize the drug as a highly selective H1-histamine-blocker of long action, which can be taken regardless of meals. High therapeutic efficacy of ebastine in treatment of various allergic diseases and conditions has been confirmed by numerous clinical studies. Including the effectiveness of the drug in long-term courses of therapy, ebastin when taken for 1 year retains its antihistamine activity, which makes it possible to prescribe the drug for 3-12 months. Antihistamine and anti-inflammatory effects of ebastine allow to stop the main symptoms of allergy, as well as throat fart, coughing fits, olfactory disorders and skin peeling. Thus, the antihistamine drug ebastine has pharmacological characteristics with a high degree of compliance with the requirements for an "ideal" antihistamine drug.
- 7 April 2023
- Published by Open Systems Publications in Лечащий врач
- No. 4(26)
Benefits of ebastine from the position of clinical pharmacology
The article reviews data on pharmacokinetics, pharmacodynamics, efficacy and safety of ebastine, presents reviews of the most significant clinical trials in the treatment of allergic diseases (allergic rhinitis, urticaria) and comparative studies with other antihistamine drugs available in the arsenal of a modern practical doctor. Data of multiple preclinical and clinical trials presented in domestic and foreign sources allow to demonstrate its effectiveness and safety widely. Ebastin is characterized as medicine with high enough safety profile due to absence of sedative, atropine-like and cardiotropic effects, absence of tachyphylaxis and interaction with other medicines, absence of influence on ability to drive motor transport and complicated mechanisms. Pharmacokinetic properties of ebastine characterize the drug as a highly selective H1-histamine-blocker of long action, which can be taken regardless of meals. High therapeutic efficacy of ebastine in treatment of various allergic diseases and conditions has been confirmed by numerous clinical studies. Including the effectiveness of the drug in long-term courses of therapy, ebastin when taken for 1 year retains its antihistamine activity, which makes it possible to prescribe the drug for 3-12 months. Antihistamine and anti-inflammatory effects of ebastine allow to stop the main symptoms of allergy, as well as throat fart, coughing fits, olfactory disorders and skin peeling. Thus, the antihistamine drug ebastine has pharmacological characteristics with a high degree of compliance with the requirements for an "ideal" antihistamine drug.
- Open Access
- 6 February 2023
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 13 (1) , 51-59
Influence of α2-Adrenoreceptor Antagonists on Electroencephalogram Characteristics after Dexmedetomidine Administration in Rabbits
The humane treatment of laboratory animals is an integral part of good laboratory practice. It remains relevant to study the anaesthetic effects of various medicinal products helping to reduce pain and distress in laboratory animals.The aim of the study was to compare the effects of the α2 blockers proroxan and atipamezole on changes in electroencephalogram rhythm index ratios after dexmedetomidine administration.Materials and methods. The study used male Soviet chinchilla rabbits weighing 3.0±0.3 kg (n=12). Study animals received single injections of 100 μg/kg dexmedetomidine subcutaneously, 50 μg/kg atipamezole intramuscularly, and 170 μg/kg proroxan intravenously (equimolar to the dose of dexmedetomidine). The effects of these medicinal products were evaluated by pharmacoelectroencephalography. The authors recorded electroencephalograms using cup electrodes and a Neuron-Spectrum-1 8-channel encephalograph (Neurosoft, Russia) with a bandwidth of 0.5–35 Hz and a sampling frequency of 500 Hz. The distribution of quantitative characteristics was checked for normality using the Shapiro–Wilk W test. The authors used one-way ANOVA with Dunnett’s post hoc test to evaluate the significance of differences for the normal distribution of quantitative characteristics; they used the nonparametric Kruskal–Wallis test with Dunn’s post hoc test for the non-normal one.Results. Dexmedetomidine administration resulted in significant two-hour changes in the rabbit brain, and the authors observed an increase in the delta rhythm and a decrease in the theta rhythm. At equimolar doses, atipamezole returned the ratios of the wave rhythm indices to the baseline values, whereas proroxan had no effect on the ratios.Conclusions. As demonstrated by the neutralisation of dexmedetomidine sedative and hypnotic effects, atipamezole can be used in veterinary for recovery from anaesthesia. Proroxan, on the contrary, is not effective in reversing the sedative effect of dexmedetomidine.
- 6 February 2023
- Published by SCEEMP in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
- Vol. 13 (1) , 51-59
Open AccessInfluence of α2-Adrenoreceptor Antagonists on Electroencephalogram Characteristics after Dexmedetomidine Administration in Rabbits
The humane treatment of laboratory animals is an integral part of good laboratory practice. It remains relevant to study the anaesthetic effects of various medicinal products helping to reduce pain and distress in laboratory animals.The aim of the study was to compare the effects of the α2 blockers proroxan and atipamezole on changes in electroencephalogram rhythm index ratios after dexmedetomidine administration.Materials and methods. The study used male Soviet chinchilla rabbits weighing 3.0±0.3 kg (n=12). Study animals received single injections of 100 μg/kg dexmedetomidine subcutaneously, 50 μg/kg atipamezole intramuscularly, and 170 μg/kg proroxan intravenously (equimolar to the dose of dexmedetomidine). The effects of these medicinal products were evaluated by pharmacoelectroencephalography. The authors recorded electroencephalograms using cup electrodes and a Neuron-Spectrum-1 8-channel encephalograph (Neurosoft, Russia) with a bandwidth of 0.5–35 Hz and a sampling frequency of 500 Hz. The distribution of quantitative characteristics was checked for normality using the Shapiro–Wilk W test. The authors used one-way ANOVA with Dunnett’s post hoc test to evaluate the significance of differences for the normal distribution of quantitative characteristics; they used the nonparametric Kruskal–Wallis test with Dunn’s post hoc test for the non-normal one.Results. Dexmedetomidine administration resulted in significant two-hour changes in the rabbit brain, and the authors observed an increase in the delta rhythm and a decrease in the theta rhythm. At equimolar doses, atipamezole returned the ratios of the wave rhythm indices to the baseline values, whereas proroxan had no effect on the ratios.Conclusions. As demonstrated by the neutralisation of dexmedetomidine sedative and hypnotic effects, atipamezole can be used in veterinary for recovery from anaesthesia. Proroxan, on the contrary, is not effective in reversing the sedative effect of dexmedetomidine.